Aditxt (NASDAQ:ADTX – Get Free Report) and Merck & Co., Inc. (NYSE:MRK – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.
Earnings and Valuation
This table compares Aditxt and Merck & Co., Inc.”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aditxt | $14,336.00 | 0.18 | -$41.71 million | ($100,788.35) | -0.00 |
| Merck & Co., Inc. | $65.01 billion | 5.47 | $18.25 billion | $1.25 | 115.39 |
Risk and Volatility
Aditxt has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.
Institutional and Insider Ownership
15.5% of Aditxt shares are owned by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Aditxt and Merck & Co., Inc.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
| Merck & Co., Inc. | 4.77% | 16.73% | 6.13% |
Analyst Recommendations
This is a summary of recent recommendations for Aditxt and Merck & Co., Inc., as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
| Merck & Co., Inc. | 0 | 11 | 16 | 0 | 2.59 |
Merck & Co., Inc. has a consensus price target of $145.76, indicating a potential upside of 1.06%. Given Merck & Co., Inc.’s stronger consensus rating and higher possible upside, analysts clearly believe Merck & Co., Inc. is more favorable than Aditxt.
Summary
Merck & Co., Inc. beats Aditxt on 13 of the 14 factors compared between the two stocks.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
About Merck & Co., Inc.
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
